03/25/2026
When someone is diagnosed with depression, the first medication works only about a third of the time. If it fails, patients and doctors often move on to another medication, then another—each trial taking four to eight weeks to know whether it helps. For many people, finding the right treatment can take months or even years.
NeuroKaire is solving this. Join us in 30 minutes on LinkedIn Live! @10:30am EST.
Today’s guest is Dr. Talia Cohen-Solal, the CEO and co-founder of NeuroKaire, a precision-psychiatry company trying to transform how we treat depression. Her team takes a simple blood sample from a patient, reprograms those cells into stem cells, and then turns them into living human neurons in the lab. Those neurons are exposed to different antidepressants while artificial intelligence analyzes how they respond—essentially creating a biological model of a patient’s brain.
The goal is to move psychiatry away from months of trial and error and toward something much more precise: identifying which medication is most likely to work for a specific individual before the prescription is even written.
Dr. Cohen-Solal trained in neuroscience at Oxford, completed her PhD at University College London, and conducted research at Columbia University before entering the biotech world. She now leads NeuroKaire’s effort to bring this “brain-in-a-dish” technology into clinical medicine.
As it is deployed at scale, it could fundamentally change how we treat depression—and potentially many other brain disorders.
1 billion members | Manage your professional identity. Build and engage with your professional network. Access knowledge, insights and opportunities.
